How to stop Mounjaro without regaining weight.

Will I regain weight if I stop Mounjaro? The honest answer

The numbers, from the highest-quality evidence:

• SURMOUNT-4 (tirzepatide — the exact molecule in Mounjaro). In 670 adults (Aronne et al., JAMA, 2024), participants lost a mean of 20.9% over a 36-week lead-in. From week 36 to 88, those switched to placebo regained 14.0% of body weight, while those who continued tirzepatide lost a further 5.5% — a treatment difference of −19.4%.
• The 2026 SURMOUNT-4 post-hoc analysis (Horn et al., JAMA Internal Medicine, 2026) found that by week 88, 82.5% of people who stopped tirzepatide had regained at least 25% of the weight they'd lost — and the more they regained, the more their blood pressure, cholesterol and blood-sugar improvements reversed.
• STEP-1 extension (semaglutide). Participants who had lost a mean of 17.3% regained 11.6 percentage points one year after stopping — leaving a net loss of just 5.6%, i.e. about two-thirds of the loss regained (Wilding et al., Diabetes, Obesity & Metabolism, 2022).
• A 2026 Cambridge meta-regression (Budini et al., eClinicalMedicine) pooling six RCTs and 3,236 participants found people regained 60% of lost weight on average one year after stopping, with regain projected to plateau around 75.3%.

Has anyone actually kept the weight off after stopping?

That's the whole point. The difference between the grim trial numbers and the reassuring real-world numbers is the maintenance plan. People who stop into a vacuum regain. People who stop into a structured system — a maintenance dose, a protein and training routine, and someone watching the scale with them — hold their results.

Do I have to take Mounjaro forever?

The strongest option has direct trial support. In SURMOUNT-MAINTAIN (Horn et al., The Lancet, 2026; N=378), people who dropped from their maximum dose to just 5mg held about 70% of their weight loss at week 112 (−16.6% from baseline), versus −21.9% for those who stayed on the full dose and only −9.9% for those switched to placebo. Just 25% on the 5mg arm regained half or more of their lost weight, versus 67% on placebo. A low dose is dramatically better than zero. The 2025 AACE obesity guidance frames it plainly: body fat is biologically defended — weight regain when you stop is physiology, not personal failure, exactly like blood pressure climbing after stopping a BP drug.

Should I taper off Mounjaro or just stop? (There is no official taper)

Tapering slowly lets you watch appetite and food noise return in slow motion instead of all at once, find your personal lowest effective dose, and catch early regain at a checkpoint before a few hundred grams becomes several kilos. A typical supervised step-down moves you down one strength at a time (for example 10mg → 5mg → 2.5mg), holding several weeks at each level while tracking weight and hunger. Tirzepatide has a half-life of about five days and clears over roughly a month, so appetite returns gradually over that window — which is precisely why checkpoints matter in the 4–12 weeks after each reduction. This is a titration down, and it deserves the same care as the titration up the dose ladder.

What's the lowest maintenance dose of Mounjaro that works?

The principle: take the lowest dose that keeps your weight stable and your hunger manageable. That minimizes both cost and side effects while preserving the metabolic benefit.

Can I stretch my dose or inject every two weeks to save money?

A cleaner, more predictable approach than stretching the interval is simply moving to a lower licensed dose (for example 5mg) at the standard weekly schedule — that's the version actually tested in SURMOUNT-MAINTAIN. If cost is the real driver, it's also worth knowing where every dose and brand sits — switching from Mounjaro to generic semaglutide is another route some people take for maintenance economics. Whatever you choose, doing it with a clinician means you'll catch it early if the spacing is letting weight creep back.

The habits that decide whether you keep it off

• Protein — defend your muscle. Roughly 20–30% of weight lost on a GLP-1 comes from lean mass. Losing muscle slows metabolism and makes regain easier. Aim above 1.2g/kg/day (many clinicians target 1.2–2.0g/kg), spread evenly across meals — even more important during a taper, when returning appetite tempts you to fill up on cheaper carbs. Our muscle-protection guide has the full protocol.
• Resistance training — rebuild what the scale hides. Strength training 2–3+ times a week, with adequate protein, is the most effective way to preserve and rebuild lean mass. Muscle is your metabolic insurance against regain.
• Sleep and food environment. Short sleep raises hunger hormones and can blunt even a drug's appetite suppression. Restructure what's in the house, your portion defaults, and liquid calories.
• Tracking and physician follow-up. Regular self-weighing and food logging let you and your clinician detect "weight drift" early — the mechanism behind the encouraging real-world numbers.

The India cost question: maintenance dose vs. stopping fully

The cost-of-maintenance math: full dose (15mg) is ₹27,500/month → ₹3.3 lakh/year; 5mg maintenance ₹17,500/month → ₹2.1 lakh/year, holding ~70% of weight loss; a 2.5mg vial about ₹14,000/month → ₹1.68 lakh/year; stopping fully is ₹0 but with a meaningful probability of regaining most of what you paid to lose. You can model your own numbers on our cost calculator or see every brand and dose side by side on our GLP-1 cost guide.

Two India-specific realities sharpen this. First, Indian health insurance does not currently cover GLP-1s for obesity, so this is entirely out-of-pocket. Second, while semaglutide (Wegovy/Ozempic) went generic in India in 2026 — its patent expired on 20 March 2026 and prices fell sharply, with Novo cutting branded Wegovy ~48% to a ~₹5,660/month starter dose — tirzepatide remains patent-protected, with no Indian generic expected until roughly 2027–2028. So there's no near-term price relief for Mounjaro specifically, which makes the maintenance-dose decision sharper.

Your staged maintenance plan

Stage 1 — before you change anything (now, while still on your full dose). Lock in the habit scaffold first: hit ≥1.2g/kg/day protein, start resistance training 2–3×/week, fix sleep, and begin near-daily self-weighing. Benchmark to proceed: consistently hitting protein and training targets for 4+ weeks. Don't begin a taper until the scaffold is in place — this is the variable that flips the trial outcome to the real-world outcome.

Stage 2 — decide your off-ramp with a clinician. Choose between an indefinite low maintenance dose, a supervised taper to zero, or dose-spacing. Decision rule: if budget allows ₹14,000–17,500/month and you want the highest certainty of holding results, default to a 5mg (or 2.5mg) maintenance dose — the only strategy with direct RCT support. Reserve a full taper to zero for those who can't sustain the cost or strongly prefer being drug-free, with intensified lifestyle support.

Stage 3 — step down slowly, monitor at every level. Reduce one strength at a time, holding 4–8 weeks each, tracking weight and appetite. Threshold that changes the plan: if you regain more than 2–3% of body weight or appetite becomes unmanageable, pause or step back up to the last dose that held — this is feedback, not failure.

Stage 4 — maintenance for life. Keep self-weighing and a quarterly physician check-in indefinitely. Re-escalation trigger: sustained regain (e.g. more than 5% from your maintenance nadir over 2–3 months) should prompt a conversation about increasing the dose or restarting, exactly as you'd adjust a blood-pressure medication.

How Kaivo does maintenance differently

Kaivo's entire model is built on one principle: a maintenance plan from day one. We don't treat reaching your goal as the end — we treat it as the moment the real work of keeping it begins. That means physician-supervised tapering with a personalised step-down schedule; finding your lowest effective dose so you spend the least for the most durable result; a protein and resistance-training scaffold prescribed before you taper; scheduled check-ins and weight tracking as an early-warning system; and honest economics — we'll model maintenance-dose cost vs. full taper with you, in rupees. Medication is bought separately at a licensed pharmacy with no Kaivo markup.

1. Aronne LJ et al. SURMOUNT-4. JAMA 2024.
2. Horn DB, Linetzky B, Davies MJ, et al. SURMOUNT-4 post-hoc analysis. JAMA Internal Medicine 2026;186(2):157–167.
3. Horn DB, Aronne LJ, Wharton S, et al. SURMOUNT-MAINTAIN. The Lancet 2026 (online 12 May 2026).
4. Wilding JPH et al. STEP-1 extension. Diabetes, Obesity & Metabolism 2022;24(8):1553–1564.
5. Budini et al. (University of Cambridge). GLP-1 weight-regain meta-regression. eClinicalMedicine 2026.
6. Gasoyan H et al. (Cleveland Clinic). Real-world discontinuation outcomes. Diabetes, Obesity and Metabolism 2026.
7. AACE obesity guidance, 2025; 2026 Eli Lilly India MRP and market reports.